Home › Funds › GILEAD SCIENCES, INC. › KYTX

GILEAD SCIENCES, INC. position in KYTX

Kyverna Therapeutics Inc. · Health Care

GILEAD SCIENCES, INC. reported holding 4,126,119 shares of KYTX (Kyverna Therapeutics Inc.) in its Q3 2026 13F filing — a position valued at US$28.1M, representing 1.92% of its reported portfolio and ranking #4 among its reported holdings. GILEAD SCIENCES, INC. has disclosed KYTX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)4.13M sh
Reported value held$28.06M
Portfolio Weight1.92%
First reportedQ4 2024
Last changeHold
Updated2026-11-06

Last updated: 2026-11-06 · Source: SEC EDGAR Form 13F-HR

How GILEAD SCIENCES, INC.'s KYTX position evolved

GILEAD SCIENCES, INC. first disclosed a stake in KYTX in Q4 2024 at 4,126,119 shares (US$15.4M). The position peaked in Q4 2025 at 4,126,119 shares, worth US$38.8M. Across 8 filings, GILEAD SCIENCES, INC. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 4,126,119 shares valued at US$28.1M.

Quarter by quarter

QuarterSharesValueChange
Q4 2024 4.13M $15.43M New
Q1 2025 4.13M $7.96M Hold
Q2 2025 4.13M $12.67M Hold
Q3 2025 4.13M $24.76M Hold
Q4 2025 4.13M $38.79M Hold
Q1 2026 4.13M $35.61M Hold
Q2 2026 4.13M $36.76M Hold
Q3 2026 4.13M $28.06M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KYTX and 13F data

KYTX (Kyverna Therapeutics Inc.) is a Health Care company. 47 other funds we track also report a position in KYTX — the largest reported positions include GordonMD Global Investments LP (US$37.8M), Bain Capital Life Sciences Investors, LLC (US$25.7M), AIGH Capital Management LLC (US$24.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KYTX

All KYTX fund holders →

FAQ

How long has GILEAD SCIENCES, INC. held KYTX?

GILEAD SCIENCES, INC. has disclosed KYTX holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is GILEAD SCIENCES, INC.'s current position in KYTX?

As of Q3 2026, GILEAD SCIENCES, INC. holds 4.13M shares of KYTX (Kyverna Therapeutics Inc.), valued at $28.06M, representing 1.92% of its reported portfolio and ranking #4.

Has GILEAD SCIENCES, INC. been buying or selling KYTX?

In the latest 13F filing (Q3 2026), GILEAD SCIENCES, INC. held unchanged its position in KYTX. The position peaked in Q4 2025 at 4.13M shares.

Which other funds hold KYTX?

Other major institutional holders of KYTX include GordonMD Global Investments LP, Bain Capital Life Sciences Investors, LLC, AIGH Capital Management LLC, among 47 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.